Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-378 + D745
- Development stage
- Unknown
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKD-378 + D745 is an investigational oral combination therapy under development by Chong Kun Dang Pharmaceutical for the treatment of type 2 diabetes mellitus. Both components are small molecule drugs. Clinical trials have focused on evaluating the pharmacokinetics, safety, and potential drug-drug interactions when these agents are administered together in healthy adults. The mechanism of action and specific targets for each component have not been publicly disclosed as of June 2025. The combination is being studied primarily for its effects on metabolic parameters relevant to diabetes management[1][2][3][5][6].
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on CKD-378 + D745.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-378 + D745.